{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:11:31Z","timestamp":1792624291649,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:02:13Z","timestamp":1745341333000},"page":"18-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group"],"prefix":"10.1016","volume":"89","author":[{"given":"Shilpa","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy M.","family":"Faltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comron","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Mendoza-Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Willliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.03.017_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.urolonc.2023.01.001","article-title":"Bladder preservation after neoadjuvant therapy\u20142021 IBCN updates part 1","volume":"41","author":"Hensley","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clon.2021.03.015","article-title":"Bladder preservation with radiotherapy: the patient perspective","volume":"33","author":"Costin","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eururo.2025.03.017_b0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clon.2022.08.023","article-title":"Checklist for improving patient communication on bladder preservation options: the patient advocate perspective","volume":"34","author":"Bangs","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eururo.2025.03.017_b0020","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN guidelines: bladder cancer. Version 4. 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417."},{"key":"10.1016\/j.eururo.2025.03.017_b0025","article-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3233\/BLC-160072","article-title":"Patterns of bladder preservation therapy utilization for muscle-invasive bladder cancer","volume":"2","author":"Rose","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.03.017_b0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","article-title":"Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations","volume":"5","author":"Hensley","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5489\/cuaj.4126","article-title":"Pathology review impacts clinical management of patients with T1-T2 bladder cancer","volume":"11","author":"Traboulsi","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2025.03.017_b0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/BLC-190239","article-title":"Bladder cancer multidisciplinary clinic (BCMC) model influences disease assessment and impacts treatment recommendations","volume":"5","author":"Diamantopoulos","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.03.017_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAS.0000000000002066","article-title":"International Society of Urological Pathology (ISUP) consensus conference on current issues in bladder cancer: progresses and challenges","volume":"48","author":"van der Kwast","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2025.03.017_b0060","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.03.017_b0065","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2010.09537.x","article-title":"Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed","volume":"106","author":"Huddart","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.017_b0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","article-title":"Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study","volume":"118","author":"Br\u00fcck","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.03.017_b0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0085","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JU.0000000000004160","article-title":"The impact of histologic subtypes on clinical outcomes after radiation-based therapy for muscle-invasive bladder cancer","volume":"212","author":"Halstuch","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0090","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0095","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0105","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0110","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0120","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0125","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.03.017_b0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0135","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (Bladder Carbogen Nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.03.017_b0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2024.08.007","article-title":"Long-term results of bladder preservation with twice-daily radiation plus 5-fluorouracil\/cisplatin or daily radiation plus gemcitabine for muscle-invasive bladder cancer-updated report of NRG\/RTOG 0712: a randomized phase 2 trial","volume":"121","author":"Coen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.03.017_b0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712\u2014a randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0150","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International Collaboration of Trialists","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2020.11.036","article-title":"Outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by (chemo)radiotherapy in the BC2001 trial","volume":"79","author":"Hussain","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0160","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0022-5347(05)68645-4","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03","volume":"162","author":"RTOG 89-03 Investigators","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0170","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","article-title":"Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder","volume":"161","author":"Khalifa","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0180","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.23.02718","article-title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: an inverse probability treatment weighted analysis","volume":"43","author":"Marcq","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","volume":"87","author":"Huddart","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.03.017_b0195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2003.10.018","article-title":"Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy","volume":"59","author":"Cowan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.03.017_b0200","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.21037\/tau.2020.03.04","article-title":"Partial cystectomy for muscle-invasive bladder cancer: a review of the literature","volume":"9","author":"Peak","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0205","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/01.ju.0000135530.59860.7d","article-title":"Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection","volume":"172","author":"Holzbeierlein","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0210","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/S0022-5347(06)00322-3","article-title":"Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience","volume":"175","author":"Kassouf","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0215","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.urology.2008.04.052","article-title":"Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma","volume":"72","author":"Smaldone","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.03.017_b0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/bju.13535","article-title":"Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy","volume":"119","author":"Golombos","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.017_b0225","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1464-410X.2011.10425.x","article-title":"Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients","volume":"109","author":"Koga","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.017_b0230","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.juro.2012.06.029","article-title":"Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis","volume":"188","author":"Knoedler","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0235","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.urology.2009.03.052","article-title":"Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis","volume":"74","author":"Capitanio","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.03.017_b0240","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","article-title":"Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0245","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","article-title":"Can patient selection for bladder preservation be based on response to chemotherapy?","volume":"97","author":"Sternberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.03.017_b0250","doi-asserted-by":"crossref","first-page":"361.e1","DOI":"10.1016\/j.urolonc.2018.04.013","article-title":"Blue light cystoscopy with Cysview Registry Group. Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry","volume":"36","author":"Daneshmand","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0255","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.euf.2018.12.002","article-title":"Urothelial carcinoma in bladder diverticula: a multicenter analysis of characteristics and clinical outcomes","volume":"6","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.03.017_b0260","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2001.19.1.89","article-title":"Transurethral resection of muscle-invasive bladder cancer: 10-year outcome","volume":"19","author":"Herr","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.017_b0265","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.juro.2010.04.008","article-title":"Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer","volume":"184","author":"Solsona","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0270","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.urology.2007.05.007","article-title":"Organ preservation for muscle-invasive bladder cancer by transurethral resection","volume":"70","author":"Leibovici","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.03.017_b0275","doi-asserted-by":"crossref","first-page":"802","DOI":"10.21037\/tau-23-124","article-title":"Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives","volume":"12","author":"Fan","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0280","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.euf.2022.10.011","article-title":"Radical transurethral resection of bladder tumor in organ-confined muscle-invasive bladder cancer: yes!","volume":"9","author":"Wood","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.03.017_b0285","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.017_b0290","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:19:41Z","timestamp":1768933181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0302283825001897"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}